Differential gene expression signatures between colorectal cancers with and without KRAS mutations: crosstalk between the KRAS pathway and other signalling pathways.

@article{Watanabe2011DifferentialGE,
  title={Differential gene expression signatures between colorectal cancers with and without KRAS mutations: crosstalk between the KRAS pathway and other signalling pathways.},
  author={Toshiaki Watanabe and Takashi Kobunai and Yoko Yamamoto and Keiji Matsuda and Soichiro Ishihara and Keijiro Nozawa and Hisae Iinuma and Hiroki Ikeuchi and Kiyoshi Eshima},
  journal={European journal of cancer},
  year={2011},
  volume={47 13},
  pages={1946-54}
}
PURPOSE KRAS mutation is an important predictive marker in determining resistance to anti-Epidermal Growth Factor Receptor (EGFR) antibody therapies. In order to clarify whether not only KRAS related signalling pathways but also other signalling pathways are altered in patients with colorectal cancers (CRCs) with KRAS mutations, we examined the differences in the gene expression signatures between CRCs with and without KRAS mutation. PATIENTS AND METHODS One-hundred and thirteen patients who… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 22 extracted citations

CMS-dependent prognostic impact of KRAS and BRAFV600E mutations in primary colorectal cancer

Annals of oncology : official journal of the European Society for Medical Oncology • 2018
View 2 Excerpts

Similar Papers

Loading similar papers…